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Abstract
Background: The evolutionary conserved cyclin-dependent kinase phosphatase hCdc14A has
been shown to play potential roles in the regulation of mitotic exit and in the centrosome
duplication cycle. We have recently shown that hCdc14A also can interact with the tumor
suppressor p53 both in vitro and in vivo and specifically dephosphorylates the ser315 site of p53 in
vitro. In this study we developed antibodies against hCdc14A to investigate the expression and
regulation of hCdc14A in human tissues and cancer cells.
Results: We show that hCdc14A is differentially expressed in human tissues and in 75 cancer cell
lines examined. Treatments with the histone deacetylase inhibitor TSA, the demethylating agent 5-
aza-2'-deoxycytodine or the proteasome inhibitor MG132 significantly induced expression of
hCdc14A in cell lines expressing low or undetectable levels of hCdc14A. There was a strong bias
for low expression of hCdc14A in cancer cell lines harboring wild-type p53, suggesting that high
Cdc14A expression is not compatible with wild-type p53 expression. We present evidence for a
role for hCdc14A in the dephosphorylation of the ser315 site of p53 in vivo and that hCdc14A
forms a complex with Cdk1/cyclin B during interphase but not during mitosis.
Conclusion: Our results that hCdc14A is differentially expressed in human cancer cells and that
hCdc14A can interact with both p53 and the Cdk1/cyclin B complex may implicate that
dysregulation of hCdc14A expression may play a role in carcinogenesis.
Background
The protein phosphatase Cdc14 has been shown to be
essential for survival and critical for the resolution of
mitosis in Saccharomyces cerevisiae and Caenorhabditis ele-
gans [1-3]. It is thought that Cdc14 in S. Cerevisiae is regu-
lated both spatially and temporally by cyclin B-Cdk and
the mitotic-exit network (MEN), which releases Cdc14
from the inhibitory RENT complex in the nucleolus in late
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B-Cdk while activating the anaphase promoting complex
(APC) that targets the destruction of mitosis-specific cyc-
lins [7,8]. In the fission yeast S. pombe, the Cdc14 homo-
logue Flp1/Clp1 appears to be differently regulated and
may have distinct functions from its homologue in S. cer-
evisiae [9]. Flp1/Clp1 is not an essential gene in S. pombe
and is thought to act in the G2 phase of the cell cycle, dur-
ing exit from mitosis and cytokinesis by regulating the
Cdc25 phosphatase and the wee1 kinase [10-15].
We previously cloned two human orthologs of the yeast
Cdc14 gene, hCdc14A and hCdc14B [16]. The hCdc14A
gene is located on band 1p21 on chromosome 1 and con-
sists of 16 exons spread over 170 kbp of DNA (genbank).
Three different splice variants of hCdc14A have been
found but it is not known whether all of them are trans-
lated into proteins. The hCdc14A has dual specific phos-
phatase activity and it can rescue Cdc14 mutants in S.
cerevisiae and S. pombe [16,17] suggesting that human
Cdc14A and yeast Cdc14 play similar functional roles
[18]. In further support of similarities in function is the
finding that hCdc14A can, like Cdc14 in S. cerevisiae, acti-
vate the anaphase promoting complex (APC) in late ana-
phase by dephosphorylating the APC co-factor Cdh1 [19]
and dephosphorylate substrates of cyclin-dependent
kinases [17,20,21]. However, hCdc14A appears to be
associated with centrosomes [19,21,22] while the yeast
Cdc14 is predominantly localized to nucleoli [4,5].
Forced over expression of hCdc14A has been shown to
result in premature centrosome splitting and mitotic spin-
dle and chromosome segregation defects while reduced
expression using siRNA techniques results in failure of
both centrosome separation and cytokinesis [21,22].
In addition to its potential role in the regulation of mitotic
exit and in the centrosome duplication cycle [19,21,22],
we have recently shown that hCdc14A can interact with
the tumor suppressor p53 both in vitro and in vivo and spe-
cifically dephosphorylates the ser315 site of p53 in vitro
[20]. This site can be phosphorylated by Cdk2/cyclin A
and Cdk1/cyclin B in vitro [23] and by aurora kinase A in
cells [24] suggesting that the hCdc14A phosphatase may
act as a Cdk and aurora kinase antagonist [20,21,25].
A previous study investigating the frequency of mutations
in the hCdc14A gene in human cancer cell lines found that
this gene is rarely mutated in human cancers [26]. How-
ever, the findings that manipulations of the protein levels
of hCdc14A result in impaired chromosome segregation
and aborted cytokinesis in human cells suggests that dys-
regulation of protein expression of hCdc14A may contrib-
ute to carcinogenesis [21,22]. To investigate the
expression levels of the hCdc14A protein in human cancer
cell lines we raised monoclonal antibodies against both
the N- and C-terminal domains of hCdc14A. Our results
show that hCdc14A is differentially expressed in human
cancer cell lines and that the low expression of hCdc14A
could be enhanced by blocking DNA methylation, his-
tone deacetylation or proteasome activity. Our results also
show that high expression of hCdc14A was rarely found in
tumors expressing wild-type p53 suggesting that over
expression of hCdc14A is not compatible with wild-type
p53 function. Finally, we found that hCdc14A interacts
with Cdc2/cyclin B during interphase but not during
mitosis suggesting that hCdc14A may ensure that Cdk1/
cyclin B activity is held in check until it is needed during
mitosis.
Results
Expression profile of hCdc14A in human tissue cells and 
cancer cell lines
It has been reported that alternative splicing of the
hCdc14A gene can give rise to three transcript variants
encoding distinct hCdc14A isoforms (LocusLink, NCBI).
To assess hCdc14A protein expression and determine
which of these isoforms are translated into proteins in
cells, we raised mouse monoclonal antibodies against
polypeptides representing sequences from both the N-ter-
minus (Ab-1) and C-terminus (Ab-2) of hCdc14A (see
Materials and Methods). Using these monoclonal anti-
bodies and Western blot we first explored the expression
of Cdc14A in human tissues. We incubated Ab-1 or Ab-2
anti-hCdc14A monoclonal antibodies with two inde-
pendent INSTA-blot membranes (IMGENEX) containing
pre-blotted proteins isolated from different human tis-
sues. It was found that both the Ab-1 and Ab-2 anti-
hCdc14A antibodies detect a single band of about 66–67
kDa in size (Figure 1A). This value corresponds well to the
size of isoform 1 of hCdc14A, which consists of 594
amino acids with a predicted molecular weight of 66.6
kDa. Thus, it appears that only isoform 1 of hCdc14 is suc-
cessfully translated into a protein product in human cells
and that both the Ab-1 and the Ab-2 antibodies work well
to detect this isoform of hCdc14A by immunoblotting.
Furthermore, the specificity of these antibodies was veri-
fied by detection of a single band in COS cells over
expressing hCdc14A-GFP (see Figure 4B). Using these
antibodies it was found that hCdc14A is differentially
expressed in human tissues with high protein expression
in brain, heart, small intestine and skeletal muscle, mod-
erate expression in spleen and low or undetectable expres-
sion in kidney, liver, lung, testis and pancreas. Differential
expression of hCdc14A mRNA in human tissues has pre-
viously been reported [16].
We next examined the expression of hCdc14A protein in
various human cancer cell lines either grown in the lab or
obtained as cell pellets from NCI. Western blot using the
hCdc14A (Ab-2) antibody revealed differential expressionPage 2 of 11
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Table 1). Low hCdc14A expression was especially com-
mon in melanoma and neuroblastoma cancer cell lines.
However, cell lines from other cancer sites showed differ-
ential expression even within a specific tumor type. It can
be noted that the HCT116 cells obtained as a cell pellet
showed low hCdc14A expression while the two HCT116
cell lines grown in our lab showed high expression. The
reason for this discrepancy is not known. Furthermore,
the MDA-MB-436 breast cancer cell line, which was previ-
ously reported to only have one wild-type hCdc14A allele,
which reportedly is silent [26], expressed a low but detect-
able amount of hCdc14A protein.
Induction of hCdc14A by 5Aza-dC and TSA
Since a previous mutational analysis of the hCdc14A
locus in a large panel of human tumor cell lines did not
reveal an abundance of deletions or mutations [26], we
thought that the lack of expression of hCdc14A in many
of the cancer cell lines tested may be due to DNA hyper-
methylation and/or histone hypoacetylation. To test this
possibility we treated some of our low hCdc14A-express-
ing cells with the demethylation agent 5Aza-dC and the
histone deacetylation inhibitor TSA. It has been shown
that these agents can reactivate the expression of genes
with DNA hypermethylation [27] or histone hypoacetyla-
tion [28].
In normal fibroblasts and RKO colon cancer cells, treat-
ment with the demethylating agent 5Aza-dC for 48 hours
did not induce expression of hCdc14A (Figure 2A). As a
positive control for demethylation we included a blot for
the MLH1 protein in RKO cells which gene is known to be
silenced by hypermethylation [27]. We did observed
some re-activation of MLH1 protein expression using
5Aza-dC in the RKO cells, although the expression level
was not impressive. In the neuroblastoma cell lines
IMR32 and SK-N-SH, the 5Aza-dC treatment resulted in a
detectable increase in hCdc14A protein expression sug-
gesting that the hCdc14A gene may be silenced by hyper-
methylation in these cells. When cells were treated with
the histone deacetylase inhibitor TSA, we observed a sub-
stantial increase in hCdc14A protein expression in all cell
lines tested. The expression of the MLH1 protein in RKO
cells was also dramatically increased by TSA. Finally, the
combination of 5Aza-dC and TSA resulted in an additive
increase of hCdc14A protein expression only in the SK-N-
SH cell line. Taken together, these results suggest that the
hCdc14A gene may be epigenetically silenced by DNA
hypermethylation and/or histone hypoacetylation in
some human cancer cell lines.
Proteasome inhibition results in increased Cdc14A 
expression
We next investigated whether hCdc14A could be induced
by cellular stresses such as UV light, the transcription
inhibitor DRB (5,6-dichloro-1-b-D-ribofuranosylbenzim-
idazole) [29,30], the Cdk and transcription inhibitor ros-
covitine {2-(1-ethyl-2-hydroxyethylamino)-6-
benzylamino-9-isopropylpurine} [31-33] or the proteas-
ome inhibitor MG132 [34]. No induction of hCdc14A
was observed in normal fibroblasts or SK-N-SH neurob-
lastoma cell following exposure to UV light, DRB or ros-
covitine (Figure 2B). However, large amounts of hCdc14A
accumulated in both cell types following treatment with
the proteasome inhibitor MG132 suggesting that
hCdc14A may normally be subject to proteasome-medi-
ated degradation.
Differential expression of hCdc14A protein in human tissues and human cancer cell linesFigu  1
Differential expression of hCdc14A protein in human tissues 
and human cancer cell lines. A) The two different anti-
hCdc14A antibodies Ab-1 (top) and Ab-2 (bottom) were 
used to analyze the amount of hCdc14A protein expression 
in different tissues using two independent INSTA-blot mem-
branes (IMGENEX) containing human tissue lysates. Both 
antibodies detect a major band of 66–67 kDa size and 
revealed a differential expression of hCdc14A in human tis-
sues. The blots were then stained with Coomassie Blue stain 
to verify even loading of proteins in the different lanes (data 
not shown). B) Equal amounts of protein from each cancer 
cell line were loaded in each lane and the amount of 
hCdc14A was detected by Western blot using the Ab-2 anti-
body. Actin protein levels were used as loading/transfer con-
trols. A tabulation of the results from this figure and from 
other experiments including other cell lines can be found in 
Table I.
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Molecular Cancer 2006, 5:25 http://www.molecular-cancer.com/content/5/1/25To investigate whether the Cdc14A phosphatase under
normal conditions is subjected to proteasome-mediated
degradation, we measured the Cdc14A protein level in
HCT116 cells incubated for different time periods in the
presence of the protein synthesis inhibitor cycloheximide.
Surprisingly, we found that the Cdc14A protein is under
non-stressed condition a stable protein with no detectable
protein turnover within 4 hours (Figure 3A). We next
investigated the time course for the accumulation of
hCdc14A proteins following proteasome inhibition with
MG132. It was found that the expression of the Cdc14A
protein sharply increased after about 8 hours (Figure 3B).
The kinetics of hCdc14A protein accumulation is very dif-
ferent from the kinetics of p53 protein accumulation fol-
lowing proteasome inhibition. Since the p53 protein is
normally rapidly degraded in a proteasome-dependent
manner, the inhibition of proteasome activity by MG132
rapidly results in the stabilization and accumulation of
p53 (Figure 3B, lower blot). Thus, even though hCdc14A
dramatically accumulates following proteasome inhibi-
tion, our results do not suggest that the hCdc14A protein
is rapidly turning over in a proteasome-dependent man-
ner.
Since MG132 incubation led to the induction of p53 prior
to the induction of hCdc14A, we thought that perhaps
p53 was mediating the expression of hCdc14A. To inves-
tigate whether the induction of hCdc14A by MG132 was
p53-dependent, we compared the induction of hCdc14A
following MG132 incubation in isogenic HCT116 cell
lines differing only in their p53 status. It was found that
hCdc14A levels increased to the same extent following
MG132 treatment in both cell lines (Figure 3C). Further-
more, hCdc14A protein levels were significantly increased
also in the p53 mutant cell line HT29. In fact, MG132 sub-
stantially increased hCdc14A expression irrespective of
p53 status in all cell lines tested.
Inverse correlation between hCdc14A expression and p53 
wild-type status
In table 1, the p53 status of each of the cell lines used in
this study are listed as well as their relative hCdc14A pro-
tein expression level. It can be noticed that most of the
p53 wild-type containing cells expressed little or undetec-
table levels of hCdc14A. Only five of the 29 cell lines
(17%) expressing non-mutant p53 expressed high levels
of hCdc14A. Two of these five cell lines (CAK-1 and SF-
Up-regulation of hCdc14A protein expression following treatment with 5aza-dC and/or TSA or MG132Figure 2
Up-regulation of hCdc14A protein expression following treatment with 5aza-dC and/or TSA or MG132. A) Cells were treated 
with 5aza-dC and TSA alone or in combination and the levels of hCdc14A and MLH1 were analyzed using Western blot and 
anti-hCdc14A (Ab-2) or anti-MLH1 antibodies. hCdc14A was up-regulated by both 5aza-dC and TSA in the two neuroblast-
oma cell lines IMR32 and SK-N-SH while in normal fibroblasts and RKO cells hCdc14A levels only responded to TSA. B) Nor-
mal fibroblasts (top) or SK-N-SH neuroblastoma cells (bottom) were either UV-irradiated (20 J/m2) or treated for 16 hours 
with the transcription inhibitor DRB (100 μM), the Cdk and transcription inhibitor roscovitine (50 μM) or the proteasome 
inhibitor MG132 (10 μM) before the cells were harvested and hCdc14A protein levels analyzed on Western blot using anti-
hCdc14A (Ab-1) or anti-actin antibodies (loading control).
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Molecular Cancer 2006, 5:25 http://www.molecular-cancer.com/content/5/1/25539) have been shown to lack a G1 cell cycle arrest follow-
ing exposure to ionizing radiation [35] suggesting that the
p53 response pathway in these cells may be abrogated by
an alternative mechanism than p53 mutation. Excluding
these two wtp53 cell lines with abrogated p53 responses
and the HCT116 cell line, with which we obtained con-
flicting results on hCdc14A expression levels between two
sources, only 2 out of 26 wt p53 cell lines (8%) expressed
high levels of hCdc14A (Figure 4A). These were the breast
cancer cell line MCF-7 and the leukemia cell line SR. In
contrast to the wt p53 expressing cells, 51% of cells with
mutant p53 expressed high levels of hCdc14A. These
results suggest that over expression of hCdc14A in cells
with wild-type p53 may not be tolerated perhaps because
these tumor cells may undergo a p53-mediated cell death.
Overexpression of hCdc14A results in dephosphorylation 
of the ser315 site of p53
We have previously shown that hCdc14A can bind to and
dephosphorylate the ser315 site of p53 in vitro [20]. To
investigate whether hCdc14A is capable of dephosphor-
ylating the ser315 site of p53 in vivo, we transfected COS
cells with a vector expressing EGFP-hCdc14A [20]. COS
cells do not normally express detectable levels of hCdc14
(Table 1). After a 48-hour expression time following trans-
fection, cells were sorted according to EGFP expression
using a FACS cell sorter and cell lysates were subjected to
Western blotting. As expected, the expression of EGFP-
hCdc14A was much higher in the cells sorted for green flu-
orescence compared to the non-green sorted cells (Figure
4B, top panel). This confirmed that the FACS sorting was
fairly clean and that our antibodies specifically detect
hCdc14A. Using a ser315 phospho-specific p53 antibody
(Cell Signaling), phosphorylation of the ser315 site of
p53 could be detected in the non-green cells but not in the
cells expressing high levels of hCdc14A-GFP (Figure 4B,
bottom panel). A non-specific band produced by this anti-
body demonstrates even loading of the samples. These
results show that over expression of hCdc14A results in
loss of ser315 phosphorylation of p53 suggesting that
hCdc14A dephosphorylates the ser315 site of p53 in vivo
as we have previously shown in vitro [20].
hCdc14A interacts with the Cdk1/cyclin B complex in 
interphase but not in mitosis
The hCdc14A and hCdc14B phosphatases have been
shown to antagonize Cdks by dephosphorylating Cdk
substrates [17,21]. Since Cdk1/cyclin B complexes co-
localize with hCdc14A to centrosomes [36,37], it is possi-
ble that hCdc14A and Cdk1/cyclin B associate with each
other. To test this hypothesis, we immunoprecipitated
cyclin B with anti-cyclin B antibodies and found that
hCdc14A co-immunoprecipitated with cyclin B in asyn-
chronized cells (Figure 4C). In contrast, when cyclin B was
immunoprecipitated from cells arrested in mitosis follow-
ing an 18-hour treatment with colchicine, no hCdc14A
was found to co-immunoprecipitate with cyclin B. As
expected Cdk1 was co-immunoprecipitated with cyclin B
from both asynchronized and colchicine-treated cells.
These results suggest that hCdc14A forms a complex with
Cdk1/cyclin B during interphase but hCdc14A separates
from Cdk1/cyclin B when cells enter mitosis.
Discussion
The hCdc14A phosphatase has recently been shown to
bind to and dephosphorylate the tumor suppressor p53
[20] as well as participate in cell cycle regulation [19,38].
Thus, dysregulation of hCdc14A may potentially play a
role in carcinogenesis. However, the frequency of muta-
tions found in the hcdc14A gene in tumor cell lines is fairly
low [26]. Using two different monoclonal anti-hCdc14A
Despite being a stable protein, Cdc14A expression can be significantly increased by incubation with the proteasome inhib tor MG132Figure 3
Despite being a stable protein, Cdc14A expression can be 
significantly increased by incubation with the proteasome 
inhibitor MG132. A) HCT116 colon cancer cells were incu-
bated for different periods of time in the presence of the 
protein synthesis inhibitor cycloheximide (10 μg/ml) followed 
by Western blot with anti-hCdc14A (Ab-1) and anti-actin 
antibodies. B) Human diploid fibroblasts were incubated for 
different periods of time with the proteasome-inhibitor 
MG132 (10 μM) followed by western blot with anti-
hCdc14A (Ab-1) or anti-p53 antibodies. C) Cells were mock 
treated or incubated for 16 hours in the presence of MG132 
(10 μM) followed by Western blot using anti-hCdc14A (Ab-
1) antibodies.
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Molecular Cancer 2006, 5:25 http://www.molecular-cancer.com/content/5/1/25antibodies we here show that the hCdc14A phosphatase is
differentially expressed in human cancer cell lines (Table
1). In melanoma and neuroblastoma cell lines hCdc14A
expression was found to be very low or not detectable
while its expression varied dramatically between different
cell lines from other tumor types. When the protein
expression of hCdc14A in the different cancer cell lines
was compared to the p53 status of the lines, a strong bias
against high hCdc14A expression was observed in wild-
type but not mutant p53-expressing cells (Figure 4A). The
strong bias for low expression of hCdc14A in cancer cells
with wild-type p53 status compared to cancer cells with
mutant p53 suggests to us that there is a strong selection
process against cells expressing high levels of hCdc14A in
the context of functional p53. It is possible that high
hCdc14A expression may activate p53 leading to cell cycle
arrest or apoptosis.
We have previously shown that hCdc14A and hCdc14B
can dephosphorylate the ser315 site of p53 in vitro. Here
we show evidence of a similar role for hCdc14A in
dephosphorylaing the ser315 site of p53 in vivo. The
ser315 site of p53 can be phosphorylated by Cdk2/cyclin
A and Cdk1/cyclin B in vitro [23] and by aurora kinase A
in cells [24]. The ser315 site of p53 has been shown to be
crucial for the binding of p53 to unduplicated centro-
somes which is important in the regulation of the centro-
some duplication cycle [39-41]. Both hCdc14A and
hCdc14B can rescue Cdc14 defects in yeast cells [16,17],
suggesting that they are functional homologues. However,
while hCdc14A localizes to centrosomes the hCdc14B
phosphatase localizes to nucleoli suggesting that the two
phosphatases may have different sets of substrates and
therefore may serve distinct functions in cells.
The association of hCdc14A to centrosomes [19,21,22,38]
and the fact that it can interact with and dephosphorylate
p53 both in vitro and in vivo [20] suggest that hCdc14A
may perhaps regulate p53 function. Moreover, its centro-
somal localization puts it in close proximity to a number
of other cell cycle kinases and their substrates such as
Cdk1 [42], Cdk2 [43,44], Plk1 [45], aurora kinases [46-
Potential role of hCdc14A in regulating p53 and Cdk1/cyclin BFigure 4
Potential role of hCdc14A in regulating p53 and Cdk1/cyclin B. A) The results in Table I were used to compare the relation-
ship between the expression level of hCdc14A and p53 status of the cell lines. The cell lines CAK-1 and SF-539 were excluded 
in the analysis since they have been shown to not arrest in G1 following exposure to ionizing radiation [35] and the HCT116 
cells were excluded because of conflicting results of hCdc14A expression between two different sources of this cell line. B) 
COS cells were transiently transfected with the pEGFP-hCdc14A vector and 24 hours later the GFP positive cells were sorted 
from the GFP negative cells and expression of hCdc14A and phosphorylation of the ser315 site of p53 was assessed using 
immunoblotting using anti-hCdc14A (Ab-2) and anti-ser315 phospho-specific p53 antibodies. C) HCT116 cells were mock 
treated or treated with the microtubular inhibitor colchicine for 18 hours. Cells were then lysed and cyclin B was immunopre-
cipitated using specific antibodies. The proteins recovered were then denatured and separated using SDS-PAGE. Anti-
hCdc14A and anti-Cdk1 antibodies were then used in immunoblotting. The star denotes the phosphorylated inactive form of 
Cdk1.
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Molecular Cancer 2006, 5:25 http://www.molecular-cancer.com/content/5/1/25Table I: Expression of Cdc14A protein in human cancer cell lines as determined by Western blot using anti-hCdc14A antibodies (Ab-
2).
Cell lines Tumor type Cdc14A expression P53 status
MCF-7 breast high wt
MCF7/ADR-RES very high mt
MDA-MB-231 high mt
MDA-MB-435 not detected mt
HS 578T not detected mt
T-47D low mt
BT-549 high ?
MCF-7* high wt
MCF-10* not detected wt
SUM-44* low ?
SUM-468* high mt
MDA-MB-436* low mt
A549/ATCC lung low wt
NCI-H460 not detected wt
NCI-H23 not detected mt
NCI-H322M not detected mt
EKVX not detected mt
NCI-H226 high mt
HCI-H522 not detected mt
HOP-62 high mt
HOP-92 high mt
HCT-116 colon low wt
HCT-15 low wt/mt
HT29 high mt
HCC2998 high mt
SW-620 not detected mt
COLO 205 low mt
KM12 low mt
HCT-116* high wt
HCT-116 p53-/-* high null
RKO* low wt
HT29* high mt
ACHN kidney not detected wt
UO-31 low wt
RXF-393 low mt
CAKI-1 high wt
SN12C high mt
786-0 high mt
TK-10 high mt
A498 low wt
OVCAR-4 ovary not detected wt
IGROV1 low wt
OVCAR-3 high mt
OVCAR-8 very high mt
OVCAR-5 high mt
SK-OV-3 low mt
SF-539 CNS high wt
SF-295 high mt
SF-268 low mt
SNB-75 high mt
SNB-19 not detected mt
U251 high mtPage 7 of 11
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Molecular Cancer 2006, 5:25 http://www.molecular-cancer.com/content/5/1/2548] and BRCA1 [49]. Our results showing that hCdc14A is
in a complex with Cdk1 and cyclin B during interphase
but not during mitosis (Figure 4C) suggest that hCdc14A
may ensure that the activity of the Cdk1/cyclin B complex
is suppressed by hCdc14A during interphase but not dur-
ing mitosis.
Hypermethylation and histone hypoacetylation of pro-
moter regions leading to inactivation of tumor suppressor
genes is a common event during carcinogenesis
[27,50,51]. The low expression of hCdc14A in some of the
cell lines tested appeared to be due to hypermethylation
and/or histone hypoacetylation of the hCdc14A promoter
since hCdc14A expression was enhanced by treatment
with the demethylating agent 5aza-dC and/or the histone
deacetylase inhibitor TSA. Our finding that the proteas-
ome inhibitor MG132 dramatically increased the
hCdc14A protein levels in all cell lines tested was surpris-
ing in light of the apparent intrinsic stability of the
hCdc14A protein. The mechanism for this enhancement
is not understood but could involve the stabilization of a
labile protein involved in the positive regulation of
hCdc14A expression. Since MG132 treatment lead to
nuclear accumulation of p53 that preceded Cdc14A accu-
mulation by about 6 hours, we first thought that p53 may
be involved in the induction of Cdc14A following protea-
some inhibition. However, when cells lacking functional
p53 were challenged with MG132 we observed a similar
increase in Cdc14A protein levels as in cells harboring
wild-type p53 ruling out a possible regulation of hCdc14A
by p53.
It has been shown that the PP1 phosphatase can be found
associated with the centrosomes [52] and that it is
involved in a feedback regulation of the aurora kinase A at
the centrosome throughout the cell cycle [53]. This find-
ing is giving precedence for a scenario in which protein
phosphatases may be able to antagonize protein kinases
at the centrosome. Since we here show that hCdc14 can
dephosphorylate the ser315 site of p53 in cells and inter-
act with Cdk1/cyclin B during interphase (Fig. 5), it is
tempting to speculate that hCdc14A may play a role in
suppressing carcinogenesis by regulating p53 and act as an
antagonist of Cdk kinases.
MOLT-4 leukemia not detected wt
SR high wt
RPMI-8226 high mt
HL-60(TB) not detected mt
K-562 low mt
CCRF – CEM not detected mt
MALME-3M melanoma low wt
SK-MEL-5 not detected wt
UACC-62 not detected wt
LOX IMVI low wt
SK-MEL-28 not detected mt
M14 not detected mt
UACC-257 not detected wt
SK-MEL-2 not detected wt
DU-145 prostate high mt
PC-3 high mt
PC-3* low mt
LNCaP* low wt
J82* bladder very high mt
SK-N-SH* neroblastoma low wt
Sk-N-MC* low wt
IMR32* not detected wt
SHSY-SY* low wt
Normal fibroblasts (NF)* others low wt
COS* not detected wt
* cell lines grown in the lab. All the other samples were from NCI.
Table I: Expression of Cdc14A protein in human cancer cell lines as determined by Western blot using anti-hCdc14A antibodies (Ab-
2). (Continued)Page 8 of 11
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The strong bias against over expression of hCdc14 in
human tumor cell lines expressing wild-type p53 suggests
that high expression of hCdc14A may be selected against
by p53-mediated cell cycle arrest or cell death. Conversely,
over expression of hCdc14A may set up a strong selection
for inactivation of p53 function in tumor cells. Together
with previous findings that hCdc14A regulates centro-
some function and cytokenesis, our findings that
hCdc14A may regulate p53 and Cdk1/cyclin B suggest
that dysregulation of hCdc14A may play an important
role in carcinogenesis.
Methods
Cell cultures
Human neonatal diploid fibroblasts, RKO colon cancer
cells and the bladder cancer cell line J82 were grown in
MEM supplemented with 10% fetal bovine serum (FBS),
2× vitamins, 2× amino acids and 1× antibiotics. RPMI
supplemented with 10% FBS and 1× antibiotics was used
for the breast cancer cell lines MCF-7, MCF-10, SUM-44,
SUM-102 and MDA-468, the colon cancer cell lines HT29,
HCT116 and HCT116 (p53-/-), the prostate cancer cell
lines PC-3 and LNCaP. The neuroblastoma cell lines SK-
N-SH, SCN-MC, IMR32 and SHSY-SY were grown in MEM
supplemented with 10% FBS and 2× amino acids and 1
mM sodium pyruvate. The COS cells were grown in
DMEM supplemented with 10% FBS and 1× antibiotics.
Cells were seeded two days prior to experiments or harvest
for Western blot. Richard F. Camalier, NCI, Frederick, MD
kindly supplied the cell pellets of the NCI 59 cancer cell
lines.
Irradiation and drug treatments
For some experiments, 5-aza-2'-deoxycytidine (5aza-dC)
and/or trichostatin A (TSA) were used in concentrations of
100 nM and 300 nM, respectively, as previously described
[27]. For UV-irradiation, cells were irradiated with 20 J/m2
of UV light (254 nm) at room temperature at a fluency of
about 0.6 J/m2/sec (UVX radiometer, UVP, Inc, Upland,
CA). MG132 (corbobenzoxy-L-leucyl-L-leucyl-L-leucinal)
(Calbiochem, La Jolla, CA) was added from a 10 mM
stock solution in DMSO to a final concentration of 10 μM.
DRB (5,6-dichloro-1-b-D-ribofuranosylbenzimidazole)
(Sigma, St. Louis, MI) was used in a 100 μM concentration
from a 50 mM stock in ethanol and roscovitine (Calbio-
chem, La Jolla, CA) was added from a 10 mM stock solu-
tion in DMSO to a final concentration of 50 μM.
Production of anti-Cdc14A monoclonal antibodies
The peptide sequences RPKSTVNTHYFSIDEEL (Ab-1),
which spans amino acids 13–29 of hCdc14A according to
Li et al. [16] and DPENKKTSSSSK (Ab-2), which spans the
amino acids 480–491, were synthesized at the Protein and
Carbohydrate Structure Facility in the Biopolymer Core,
University of Michigan Medical School. These peptides
were purified before being conjugated to KLH and used to
immunize mice (performed at the University of Michigan
Hybridoma Facility). Blood sera from the immunized
mice were screened by ELISA using the KLH-Cdc14A pep-
tides as a positive control and KLH-p53 peptides as a neg-
ative control. The spleen cells from one of the immunized
mice in each set were then used to produce hybridoma
cells that were clonally expanded and further screened by
ELISA.
Immunoblotting
Cells were prepared for western blots as previously
described [54,55]. The supernatant from the final clones
selected producing monoclonal anti-Cdc14A antibodies
Ab-1 and Ab-2 were used in a 1:5 and a 1:10 dilution,
respectively. Both Ab-1 (N-terminus) and Ab-2 (C-termi-
nus) recognized a single major band on Western blots in
the size range of 66–67 kDa which is the expected size for
the 594 amino acids protein (66.6 m.w.). In addition to
the major band, the antibody detected a minor band at
about 20 kDa. While the intensity of the major band var-
ied significantly between different cell lines, the 20-kDa
band was invariant. For the examination of Cdc14A
expression in human tissues, an INSTA-blot (IMB-103,
IMGENEX, San Diego, CA) was used. Similar protein con-
centrations in the different lanes on the INSTA-blot were
confirmed by using the Ponceau S. protein stain. For
Western blot of the Cdc14A from cancer cell lines, equal
amounts of proteins were loaded onto 10% polyacryla-
mide/SDS gels and after blotting, equal transfer of pro-
teins was confirmed by staining the membranes with anti-
actin antibodies (Sigma Chemical Co., St Louis, MO) and
Coomassie Blue stain. Other antibodies used for Western
blot were anti-MLH1 (BD Biosciences Pharmingen, San
Diego, CA) anti-p53 (Ab-2, Oncogene Research Products,
Model outlining the role of hCdc14A as a p53-targeting phos-phataseFigur  5
Model outlining the role of hCdc14A as a p53-targeting phos-
phatase. The ser315 site of p53 can be phosphorylated by 
aurora kinase A and the Cdk1/cyclin B complex. In this study 
we show evidence that hCdc14A can antagonize these 
kinases by dephosphorylating the ser315 site in cells. In addi-
tion, by interacting with Cdk1/cyclin B during interphase, 
hCdc14A may further antagonize Cdk1/cyclin B-mediated 
phosphorylation until cells enter mitosis.Page 9 of 11
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bodies (Cell Signaling).
Transient transfection and FACS sorting
Cells were transiently transfected with the pEGFP-
hCdc14A vector [16] using the FuGENE6 transfection
agent according to description of the manufacturer (Boe-
hringer Mannheim, Mannheim, Germany). Cells were
then incubated for 24 hours before the cells were
trypsinized and sorted according to their expression of
green fluorescence using FACS flow sorting. The two frac-
tions were then prepared for immunoblotting
Immunoprecipitation
HCT116 cells were mock treated or incubated with colch-
icine (0.5 μg/ml) for 18 hours before the cells were col-
lected and cyclin B was immunoprecipitated using anti-
cyclin B1 antibodies (Santa Cruz) as previously described
[56]. The immunoprecipitates were then run on 10%
SDS/PAGE and proteins were visualized as described for
western blots using our monoclonal anti-hCDC14A anti-
bodies (Ab-2) or anti-Cdk1 antibodies (Santa Cruz).
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